Canada · Delayed Price · Currency is CAD Spectral Medical Company Description
Spectral Medical Inc., together with its subsidiaries, focuses on the development and commercialization of products for the treatment of septic shock and renal disease in North America.
The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream.
It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies; and develops platform for renal replacement therapy.
The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014.
Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.
| Country | Canada |
| Founded | 1991 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 29 |
| CEO | Christopher Seto |
Contact Details
Address: 135 The West Mall Toronto, ON ON Canada | |
| Phone | 416-626-3233 |
Stock Details
| Ticker Symbol | EDT |
| Exchange | Toronto Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| ISIN Number | CA8475771033 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Christopher Seto | Chief Executive Officer, Interim Chief Financial Officer and Director |
| Prof. John A. Kellum M.D. | Chief Medical Officer |